Driving the process development of recombinant therapeutic products with automated MS-based target peptide mapping
How do you shorten CMC decision cycles without sacrificing depth of product understanding? In this presentation, Diego Bertaccini walk through an automated, mass spectrometry–based Multi-Attribute Method (MAM) workflow for targeted peptide mapping—built for high-throughput process development and early process characterization, and designed to scale toward later-stage QC needs. You’ll see how automation + data modeling can deliver faster analytical turnaround and more confident process decisions.
Learning points:
- How MAM enables site-specific, multi-attribute quantification of PQAs/PTMs—and where it can replace/streamline conventional assays
- Practical approaches to integrate MAM into end-to-end robotics to reduce manual touchpoints and accelerate analytics turnaround
- How optimized, high-throughput MAM data supports stronger statistical process models (including low-level PTMs) to guide process setpoints and decisions
- Real workflow optimization examples (e.g., digestion / missed-cleavage and alkylation condition testing) to improve robustness and reproducibility
Who should attend?
- Analytical Development / MS scientists implementing (or scaling) peptide mapping and MAM workflows
- Process Development / CMC teams who need faster feedback on CQAs/PQAs to iterate process conditions and clone selection
- Automation / high-throughput platform owners integrating sample prep and analytics across connected lab equipment
- QC / late-stage readiness stakeholders evaluating how early-stage MAM can be streamlined toward regulated environments
This webinar is a recording from the Omics innovations for the biopharmaceutical industry seminar on December 11, 2025 in Strasbourg.
Cannot attend on February 17? Please register anyway to automatically receive access to the recording.
Presenter: Diego Bertaccini (Analytical Development and Innovation Laboratory Manager, Merck Group)
